Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etanercept biosimilar - Coherus Biosciences

Next Previous
Drug Profile

Etanercept biosimilar - Coherus Biosciences

Alternative Names: BAX 2200; CHS-0214

Latest Information Update: 17 Nov 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Coherus Biosciences
  • Developer Coherus BioSciences; Daiichi Sankyo Company
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 01 Jul 2020 the US Court of Appeals for the Federal Circuit upholds the validity of patents of Amgen, regarding therapeutic fusion protein in etanercept
  • 01 Jul 2020 Discontinued - Phase-III for Plaque psoriasis in USA, Australia, Canada, Germany, Israel, Poland, South Africa, Spain, United Kingdom (SC)
  • 01 Jul 2020 Discontinued - Phase-III for Rheumatoid arthritis (Treatment-experienced) in USA, Belarus, France, Germany, Hungary, Israel, Poland, Russia, South Africa, Spain, United Kingdom (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top